|
| 替加环素治疗感染性疾病安全性的Meta分析 |
| Meta analysis of Safety Induced by Tigecycline in the Therapy of Infectious Diseases |
| |
| DOI： |
| 中文关键词: 替加环素 感染性疾病 安全性 Meta分析 |
| 英文关键词:Tigecycline Infectious diseases Safety Meta analysis |
| 基金项目: |
|
| 摘要点击次数: 1054 |
| 全文下载次数: 1286 |
| 中文摘要: |
| 摘 要 目的:运用Meta分析方法对替加环素治疗感染性疾病的安全性评价。方法：检索中、英文数据库有关替加环素抗感染治疗的随机对照临床试验文献，制定文献纳入标准，使用RevMan5.0软件对纳入文献的总体死亡率与不良反应发生率进行Meta分析。结果：最终纳入文献18篇，替加环素在总体死亡率方面高于对照组药物（OR=1.34, 95%CI:1.05～1.70, P=0.02），在总体不良反应发生率方面也高于对照组药物（OR=1.41, 95%CI:1.21～1.64, P＜0.000 01），差异均有统计学意义。结论：虽然替加环素具有独特的抗菌活性，但应当慎重选择，并给予使用者更加密切的监护。 |
| 英文摘要: |
| ABSTRACT Objective:To evaluate the safety of tigecycline in the therapy of infectious diseases by Meta analysis method. Methods: Literatures of randomized clinical studies about tigecycline in the therapy of infectious diseases published before were retrieved from CNKI, WanFang database, MEDLINE, Embase, Cochrane library,‘ISRCTN Register’ and ‘ClinicalTrials.gov’, Meta analysis was performed by the statistical software RevMan5.0. Results:Eighteen studies were analyzed. On treatment safety, the outcomes suggested that tigecycline groups were numerically higher than control group on incidence of ADRs and overall mortality ( for incidence of ADRs,OR=1.41，95%CI:1.21-1.64, P＜0.000 01; for overall mortality,OR=1.34, 95%CI:1.05-1.70,P=0.02). Conclusion:According to the outcomes, tigecycline was higher on incidence of AEs and higher risk of overall mortality. So, although there were unique advantages, doctors should be prudently and pay close attention to patients with tigecycline. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
